Researchers at Kiel University have cracked a crucial code in the fight against one of medicine's most dangerous adversaries: they've discovered how to weaken the notoriously stubborn bacterium Pseudomonas aeruginosa by strategically sequencing two antibiotics to work in tandem.
The discovery matters because antibiotic resistance has become one of the greatest threats to global public health. Experts warn that without action, antimicrobial-resistant infections could cause around 50 million deaths worldwide annually by mid-century. P. aeruginosa, a Gram-negative bacterium that causes acute and chronic infections especially in hospitalized and immunocompromised patients, exemplifies the crisis: it's classified by the World Health Organization as a high-priority pathogen precisely because it resists multiple antibiotics and adapts rapidly to treatment.
The Kiel team, led by Professor Hinrich Schulenburg and first author Dr. Florian Buchholz, identified a phenomenon called negative hysteresis—a process where pre-treatment with one antibiotic sensitizes bacterial cells to a second drug, dramatically amplifying its effectiveness. Their research, published in Nature Communications, shows that when P. aeruginosa is first exposed to a beta-lactam antibiotic, it doesn't kill the bacteria outright. Instead, it induces membrane stress in the bacterial cell wall, making it significantly more permeable to a subsequently administered aminoglycoside antibiotic. This enhanced permeability doesn't just kill the pathogen more reliably—it also inhibits the bacteria's ability to adapt and evolve resistance.
What makes this finding particularly powerful is its simplicity and reliability. The research team demonstrated that negative hysteresis represents a general weak spot in P. aeruginosa that can be triggered even by low doses of the sensitizing antibiotic. This isn't a phenomenon unique to laboratory strains; it works across different strains of the bacterium, offering real clinical promise. The mechanism itself is elegant: the physiological damage caused by the first antibiotic creates vulnerability that the second exploits, with the bacteria unable to mount the adaptive defenses they typically rely on.
The implications are significant not just for P. aeruginosa, but for the broader antimicrobial resistance crisis. Schulenburg's research group has long studied the mechanisms of resistance evolution in this particular pathogen, investigating how bacteria develop both genetic and non-genetic adaptations to drug exposure. By understanding how to combine existing antibiotics effectively—rather than waiting for entirely new drugs to be developed—the team offers a path to preserve antibiotic efficacy while simultaneously slowing resistance evolution.
P. aeruginosa infections are becoming increasingly problematic, with growing numbers of strains classified as multi-drug resistant, insensitive to three or more different antibiotics. Hospital patients and those with chronic lung diseases like cystic fibrosis remain particularly vulnerable. This research, conducted as part of Kiel University's Research Training Group TransEvo, points toward a strategy that healthcare systems could implement using drugs already available—a crucial advantage given how long it takes to bring new antibiotics to market.
The path forward now involves translating this laboratory insight into clinical practice. But the underlying principle is sound: sometimes the most elegant solutions to old problems come not from inventing entirely new tools, but from understanding how to deploy existing ones with precision and strategy.